Equine IL-17A Recombinant Protein

Catalog Number:: RP0078E
Availability:: In stock
Application:: Cell Culture, ELISA Standard, ELISpot Control, Western Blot Control
100% Homology:: Equus caballus (horse)

Equine IL-17A (catalog RP0078E) is a yeast-derived cytokine supplied lyophilized without carrier protein in 10% trehalose; it has no affinity tags and is naturally endotoxin-free, and should be reconstituted in sterile PBS that contains at least 0.1% carrier protein. The protein is ~14.9 kDa, 130 amino acids long (full sequence provided), and >98% pure by SDS-PAGE, with 100% amino-acid homology to horse. Store at -20°C (stable up to twelve months from date of receipt; working aliquots with carrier protein stable ~3 months) and avoid repeated freeze/thaw cycles. Product origin is the USA. Kingfisher Biotech products are supplied for research applications and are not intended for medicinal, diagnostic, or therapeutic use. It is commonly used to study IL-17 signaling, neutrophil recruitment and activation, mucosal immunity and Th17 responses; typical experimental uses include cell-culture stimulation and dosing studies, chemotaxis and neutrophil-activation assays, ELISA and neutralization assays, flow-cytometry and Western blot controls, and antibody generation/validation.

Amino Acid Sequence	GIVIPQNPEC PNTGDKNFPQ NVKINLNVLN RKTNSRRASD YHNRSTSPWN LHRNEDPERY PSVIWEAKCR HLGCVNAEGK VDFHMNSVPI QQEILVLRRE SQNCPHSFQL EKMLVAVGCT CVTPIVRHMG (130)
Endotoxin	Naturally endotoxin-free

Storage Conditions	-20°C
Molecular Weight	34.6 kda
Purity	>98% as visualized by SDS-PAGE analysis.
Country Of Origin	USA

Equine IL-17A (Interleukin-17A) is a pro-inflammatory cytokine belonging to the IL-17 family that plays a central role in host defense and inflammatory responses in horses (Equus caballus). IL-17A is produced primarily by Th17 cells, as well as by γδ T cells and other innate lymphoid populations, in response to microbial infection and immune stimulation. It acts on epithelial, endothelial, and stromal cells to induce expression of pro-inflammatory cytokines, chemokines (such as CXCL8), and antimicrobial peptides, thereby promoting neutrophil recruitment and enhancing mucosal and barrier immunity in the respiratory, gastrointestinal, and reproductive tracts. In healthy horses, basal IL-17A expression is generally low, but levels increase during bacterial and fungal infections, parasitic disease, and inflammatory conditions. Elevated IL-17A has been implicated in equine asthma (recurrent airway obstruction), inflammatory airway disease, endometritis, and other neutrophil-driven inflammatory disorders. In veterinary and comparative medicine research, equine IL-17A serves as an important biomarker of Th17-mediated immune activation and neutrophilic inflammation, providing insight into disease pathogenesis, vaccine responses, and potential immunomodulatory therapeutic strategies in equine health.

Choose a size

Please choose a size to see price

RELATED MEDIA